1
|
Scailteux LM, Balusson F, Oger E, Vincendeau S, Mathieu R. Androgen deprivation therapy prescription, blood and bone-density testing in a French population-based study exploring adherence to the French prostate cancer guidelines. Minerva Urol Nephrol 2020; 73:845-848. [PMID: 32298066 DOI: 10.23736/s2724-6051.20.03683-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The safety profile of androgen deprivation therapy (ADT) is well known, and cardiovascular and osteoporosis risk factors should be assessed before ADT initiation. In order to examine whether the French Committee of Urologic Oncology Prostate Cancer (PCa) Guidelines were properly followed by clinicians, including urologists, oncologists and radiotherapists, we used a nationwide comprehensive cohort of prostate cancer patients, who were new ADT users in 2011 and were followed-up to 2013. Reimbursements for biological examinations and prescribers were identified, as well as PCa specialist consultations at drug initiation. Our results in this French cohort showed that the proportions of patients resorting to specialized care between one year and 3 months before ADT initiation and in the 6 months following was around 40% for fasting glucose and 30% for lipid assessments. Bone densitometry was performed in approximately 1% of patients. In the 12 months after ADT initiation, 75% of the patients were seen by a urologist and about 47% by an oncologist or a radiotherapist. Overall, there is still room for improvement in terms of ADT monitoring by clinicians and in the information provided to general practitioners and patients regarding the expected adverse effects of this treatment.
Collapse
Affiliation(s)
- Lucie-Marie Scailteux
- Department of Clinical Pharmacology, Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, Rennes, France - .,Pharmacoepidemiology and Health Services Research, University of Rennes, Rennes, France -
| | - Frédéric Balusson
- Pharmacoepidemiology and Health Services Research, University of Rennes, Rennes, France
| | - Emmanuel Oger
- Department of Clinical Pharmacology, Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, Rennes, France.,Pharmacoepidemiology and Health Services Research, University of Rennes, Rennes, France
| | | | - Romain Mathieu
- Department of Urology, University Hospital of Rennes, Rennes, France.,Inserm, EHESP, CHU Rennes, Institut de Recherche en Santé, Environnement et Travail - IRSET, University of Rennes, Rennes, France
| |
Collapse
|